PE20030412A1 - Tecnica de transfeccion intensificada - Google Patents
Tecnica de transfeccion intensificadaInfo
- Publication number
- PE20030412A1 PE20030412A1 PE2001000963A PE2001000963A PE20030412A1 PE 20030412 A1 PE20030412 A1 PE 20030412A1 PE 2001000963 A PE2001000963 A PE 2001000963A PE 2001000963 A PE2001000963 A PE 2001000963A PE 20030412 A1 PE20030412 A1 PE 20030412A1
- Authority
- PE
- Peru
- Prior art keywords
- cells
- protein
- plasmides
- mammal
- heterological
- Prior art date
Links
- 238000000034 method Methods 0.000 title 1
- 238000001890 transfection Methods 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 9
- 108090000623 proteins and genes Proteins 0.000 abstract 6
- 102000004169 proteins and genes Human genes 0.000 abstract 6
- 230000014509 gene expression Effects 0.000 abstract 3
- 239000013612 plasmid Substances 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 108091023040 Transcription factor Proteins 0.000 abstract 2
- 208000011691 Burkitt lymphomas Diseases 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 abstract 1
- 101150059079 EBNA1 gene Proteins 0.000 abstract 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 abstract 1
- 108010002350 Interleukin-2 Proteins 0.000 abstract 1
- 241000288906 Primates Species 0.000 abstract 1
- 102000040945 Transcription factor Human genes 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 210000004754 hybrid cell Anatomy 0.000 abstract 1
- 108040006852 interleukin-4 receptor activity proteins Proteins 0.000 abstract 1
- 238000012423 maintenance Methods 0.000 abstract 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 abstract 1
- 230000000392 somatic effect Effects 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/108—Plasmid DNA episomal vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
SE REFIERE A UN SISTEMA VECTOR DE EXPRESION GENICA EN CELULAS DE MAMIFERO QUE INCLUYE UNA PLURALIDAD DE PLASMIDOS Y COMPRENDE: a)UN SISTEMA DE MANTENIMIENTO EPISOMAL QUE COMPRENDE UN ELEMENTO oriP Y UN GEN QUE EXPRESA EBNA1 ESTAN EN EL MISMO PLASMIDO O EN PLASMIDOS SEPARADOS Y/O EN LAS CELULAS HUESPED; b)UN FUERTE PROMOTOR/INTENSIFICADOR TAL COMO CMV; c)UN COMPLEJO DE TRANSACTIVACION DE PROTEINAS QUE INCLUYE TANTO EL ELEMENTO TAT (GEN TRANSACTIVADOR) COMO TAR (SECUENCIA DE RESPUESTA TRANSACTIVADORA) QUE SE ENCUENTRAN EN EL MISMO PLASMIDO O EN PLASMIDOS SEPARADOS O EN CELULAS DE EXPRESION, TAMBIEN INCLUYE LA PROTEINA BMLF1, ORIGINADA A PARTIR DEL VIRUS DE EPSTEIN BARR; d)ADN QUE CODIFICA PARA LA PROTEINA HETEROLOGA QUE SE SELECCIONA DE UNA MUTEINA DE IL-2 QUE TIENE UNA SUSTITUCION DE AMINOACIDOS (N88R) IL-2SA E IL-4R; SIENDO LA LINEA CELULAR DE UN PRIMATE, LINEA CELULAR HIBRIDA SOMATICA HUMANA ATCC, CRL-12568 DERIVADA DE FUSIONES CELULARES DE RINON EMBRIONARIO HUMANO 293S Y CELULAS DE ORIGEN DE LINFOMA DE BURKITT P3HR-1 (HBK11), CELULAS 293 QUE EXPRESAN EBNA 1, OBTENIDAS DE INVITROGEN (293EBNA), 293. LAS PROTEINAS HETEROLOGAS EXPRESADAS POR CELULAS DE MAMIFEROS TIENEN HABITUALMENTE CUALIDADES MEJORES O MAS CONVENIENTES PARA CARACTERIZAR LAS PROTEINAS QUE LAS PROTEINAS EXPRESADAS A PARTIR DE CELULAS DE NO MAMIFEROS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67584700A | 2000-09-28 | 2000-09-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20030412A1 true PE20030412A1 (es) | 2003-06-26 |
Family
ID=24712193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2001000963A PE20030412A1 (es) | 2000-09-28 | 2001-10-23 | Tecnica de transfeccion intensificada |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1356069B1 (es) |
| JP (1) | JP5022555B2 (es) |
| AR (1) | AR035495A1 (es) |
| AU (1) | AU2001289075A1 (es) |
| CA (1) | CA2420771C (es) |
| CO (1) | CO5270027A1 (es) |
| DE (1) | DE60119386T2 (es) |
| DO (1) | DOP2001000254A (es) |
| EC (1) | ECSP014147A (es) |
| ES (1) | ES2263652T3 (es) |
| GT (1) | GT200100194A (es) |
| HN (1) | HN2001000215A (es) |
| MY (1) | MY139948A (es) |
| PE (1) | PE20030412A1 (es) |
| SV (1) | SV2002000640A (es) |
| TW (1) | TWI239354B (es) |
| UY (1) | UY26947A1 (es) |
| WO (1) | WO2002027005A2 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006121995A (ja) * | 2004-10-29 | 2006-05-18 | Tokyo Medical & Dental Univ | Ｅｂｎａ１変異体 |
| CN101341252B (zh) | 2005-10-28 | 2011-08-17 | 弗·哈夫曼-拉罗切有限公司 | 啮齿动物细胞中的蛋白质表达 |
| ES2699718T3 (es) | 2009-09-15 | 2019-02-12 | Medlmmune Ltd | Células para expresión transitoria y usos de las mismas |
| WO2014092094A1 (ja) * | 2012-12-11 | 2014-06-19 | タカラバイオ株式会社 | 発現カセット |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9003010D0 (en) * | 1990-02-09 | 1990-04-04 | Glaxo Group Ltd | Gene expression in yeast cells |
| US6150515A (en) * | 1996-07-03 | 2000-11-21 | Massachusetts Institute Of Technology | Tat-SF: cofactor for stimulation of transcriptional elongation by HIV-1 Tat |
| US6465251B1 (en) * | 1996-11-13 | 2002-10-15 | Dana-Farber Cancer Institute, Inc. | Method of promoting b-cell proliferation and activation with CD40 ligand and cyclosporin |
| DZ2788A1 (fr) * | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
| IT1302403B1 (it) * | 1998-11-06 | 2000-09-05 | Angeletti P Ist Richerche Bio | Cellule per la produzione di vettori adenovirali difettivi, metodoper la loro preparazione e loro uso. |
| US6136599A (en) * | 1998-12-10 | 2000-10-24 | Bayer Corporation | Human hybrid host cell for mammalian gene expression |
-
2001
- 2001-09-12 MY MYPI20014270A patent/MY139948A/en unknown
- 2001-09-14 CA CA2420771A patent/CA2420771C/en not_active Expired - Fee Related
- 2001-09-14 DE DE60119386T patent/DE60119386T2/de not_active Expired - Lifetime
- 2001-09-14 AU AU2001289075A patent/AU2001289075A1/en not_active Abandoned
- 2001-09-14 WO PCT/US2001/028681 patent/WO2002027005A2/en not_active Ceased
- 2001-09-14 JP JP2002530768A patent/JP5022555B2/ja not_active Expired - Fee Related
- 2001-09-14 EP EP01968864A patent/EP1356069B1/en not_active Expired - Lifetime
- 2001-09-14 ES ES01968864T patent/ES2263652T3/es not_active Expired - Lifetime
- 2001-09-21 CO CO01081102A patent/CO5270027A1/es not_active Application Discontinuation
- 2001-09-25 GT GT200100194A patent/GT200100194A/es unknown
- 2001-09-25 HN HN2001000215A patent/HN2001000215A/es unknown
- 2001-09-26 DO DO2001000254A patent/DOP2001000254A/es unknown
- 2001-09-26 UY UY26947A patent/UY26947A1/es not_active Application Discontinuation
- 2001-09-27 TW TW090123834A patent/TWI239354B/zh not_active IP Right Cessation
- 2001-09-27 SV SV2001000640A patent/SV2002000640A/es active IP Right Grant
- 2001-09-27 AR ARP010104563A patent/AR035495A1/es active IP Right Grant
- 2001-09-27 EC EC2001004147A patent/ECSP014147A/es unknown
- 2001-10-23 PE PE2001000963A patent/PE20030412A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002027005A3 (en) | 2003-07-31 |
| AR035495A1 (es) | 2004-06-02 |
| DE60119386T2 (de) | 2007-04-19 |
| TWI239354B (en) | 2005-09-11 |
| JP5022555B2 (ja) | 2012-09-12 |
| GT200100194A (es) | 2002-05-16 |
| DE60119386D1 (de) | 2006-06-08 |
| JP2004509642A (ja) | 2004-04-02 |
| SV2002000640A (es) | 2002-10-24 |
| WO2002027005A9 (en) | 2003-02-06 |
| UY26947A1 (es) | 2002-04-26 |
| CO5270027A1 (es) | 2003-04-30 |
| EP1356069B1 (en) | 2006-05-03 |
| CA2420771C (en) | 2010-12-21 |
| CA2420771A1 (en) | 2002-04-04 |
| DOP2001000254A (es) | 2002-06-15 |
| HN2001000215A (es) | 2003-11-11 |
| ES2263652T3 (es) | 2006-12-16 |
| WO2002027005A2 (en) | 2002-04-04 |
| MY139948A (en) | 2009-11-30 |
| ECSP014147A (es) | 2002-05-23 |
| EP1356069A2 (en) | 2003-10-29 |
| AU2001289075A1 (en) | 2002-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8507277B2 (en) | Nonviral vectors for delivering polynucleotides | |
| US8133733B2 (en) | Nonviral vectors for delivering polynucleotides to target tissues | |
| ES2411962T3 (es) | Métodos y composiciones para suministrar polinucleótidos | |
| WO2016080795A1 (ko) | 두 개의 벡터로부터 발현된 cas9 단백질을 이용한 유전자 발현 조절 방법 | |
| US20220195416A1 (en) | Rna site-directed editing using artificially constructed rna editing enzymes and related uses | |
| IL274528B1 (en) | Engineered CAS9 systems for eukaryotic genome modification | |
| ATE192500T1 (de) | Rekombinante viren vektoren zur expression in muskelzellen | |
| ZA200007403B (en) | Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals. | |
| ES8605039A1 (es) | Procedimiento para preparar una vacuna que comprende un derivado truncado, libre de una membrana de un tipo fijado a una membrana que tiene determinantes antigenicos expuestos. | |
| ES2061996T3 (es) | Regiones no esenciales de avipoxvirus. | |
| NO963358D0 (no) | Vertsvektor-system til anvendelse i genterapi | |
| CN111575319B (zh) | 一种高效的crispr rnp和供体dna共位介导的基因插入或替换方法及其应用 | |
| BR9912498A (pt) | Expressão de peptìdios eucarióticos em plastìdio de plantas | |
| PE20030412A1 (es) | Tecnica de transfeccion intensificada | |
| US12291706B2 (en) | Methods for screening variant of target gene | |
| DE69627644T2 (de) | Vektoren, die therapeutische gene fuer antimikrobielle peptide enthalten, zur verwendung in der gentherapie | |
| WO1994013812A3 (en) | Novel entomopoxvirus genes, proteins and methods of use thereof | |
| CN113564145B (zh) | 用于胞嘧啶碱基编辑的融合蛋白及其应用 | |
| EP0915166B1 (de) | DNA-Virus-Vektoren und Verfahren zu ihrer Herstellung | |
| CA3234642A1 (en) | Transposases and uses thereof | |
| JP6956995B2 (ja) | ゲノム編集方法 | |
| WO2021061946A2 (en) | A promoter specific for non-pigmented ciliary epithelial cells | |
| WO2024220598A9 (en) | Lentiviral vectors with two or more genomes | |
| US20230109885A1 (en) | Methods for screening variant of target gene | |
| ES2300200B1 (es) | Transposon hsmar2 y su uso en la generacion de vectores utiles en terapia genica somatica. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |